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Артеріальна гіпертензія (АГ) – найпоширеніше в світі серцево-судинне захворювання і є причиною інва-
лідизації населення розвинених країн світу. Особливістю фармакотерапії при АГ є довічний прийом лі-
карських препаратів. Показники економічної оцінки ефективності різних методів лікування сприяють 
вибору фармакотерапії, яка забезпечить пацієнту найбільшу результативність лікування з урахуванням 
фінансових можливостей конкретного хворого. Головними завданням антигіпертензивної терапії є до-
сягнення цільового рівня артеріального тиску (АТ), захист органів-мішеней і позитивний вплив на фак-
тори ризику серцево-судинних ускладнень. Метод «затрати-ефективність» дає можливість співста-
вити витрати при однаковій терапевтичній ефективності, що і було метою нашого дослідження.  
Матеріали та методи. Досліджено 100 протоколів медичних карток стаціонарних хворих. Виділено 2 
групи хворих: перша група для лікування АГ отримувала кандесартан, а друга група – раміприл. До уваги 
бралися параметри: досягнення цільового АТ, а також можливі ускладнення лікарської терапії – гіпо-
тензія, кашель, ангіоневротичний набряк. Для оцінки вартості лікування на тлі застосування раміприлу 
та кандесартану був проведений фармакоекономічний аналіз «затрати-ефективність». 
Результати дослідження. За допомогою методу „вартість-ефективність” було проведено аналіз ра-
міприлу і кандесартану. Були розраховані мінімальні, середні та максимальні вартості разової, добової 
та курсової дози і розрахована вартість нормалізації АТ. Отримані нами дані свідчать про меншу вар-
тість лікування раміприлом. Результати аналізу ефективності препаратів продемонстрували, що ра-
міприл більш ефективний у досягненні цільового АТ, але відсоток побічних ефектів серед яких серцева 
недостатність і кашель був суттєво вищим. Отримані дані вказують на високу терапевтичну ефекти-
вність кандесартану і раміприлу, що дозволяє зробити висновки: 
Висновки. Найбільш ефективним у досягненні цільового АТ був раміприл по зрівнянню з кандесартаном. 
Аналіз ефективності дії лікарських препаратів встановив, що раміприл має побічні ефекти і викликає 
кашель і серцеву недостатність, а кандесартан може стати причиною ангіоневротичного набряку і гі-
потензії. В ході аналізу прямих затрат на лікування АГ, на основі діючих стандартів надання медичної 
допомоги хворим з АГ було встановлено, що найменш витратним є лікування раміприлом. Проведений 
аналіз ≪витрати – ефективність≫, продемонстрував, що найбільшою фармакоекономічною перевагою 
має раміприл 
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1. Introduction 
Arterial hypertension (AH) – the most common 
cardiovascular disease in the world, which has a signifi-
cant impact on the structure of disability and mortality of 
the population of industrialized countries of the world. 
Hypertension is often accompanied by complications 
such as myocardial infarction (MI), stroke, chronic heart 
failure (CHF). The peculiarity of pharmacotherapy in 
hypertension is usually the lifelong use of medicines. The 
drugs used today have received a solid evidence base, as 
well as long stages of clinical and experimental research. 
Indicators of economic evaluation of the effectiveness of 
various treatments are criteria that help to select the 
method of pharmacotherapy, which will provide the 
patient with the greatest benefit of treatment and the most 
acceptable quality of life, taking into account the finan-
cial capabilities of a particular patient or public health 
care. The doctor prescribes one or another effective med-
ication based on its cost, which minimizes costs and 
optimizes the treatment itself [1]. 
2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
In order to assess the quality of medicinal prod-
ucts, it is necessary to apply modern performance crite-
ria. First of all, this is the effectiveness (medical and 
social efficiency) – the degree of achievement of the 
desired result of providing medical care taking into ac-
count the current level of development of medicine, ra-
tionality (scientific validity) – the frequency of applica-
tion of certain proven useful medical technologies for 
specific diseases or in specific clinical situations; safe 
use – introduction without significant risk to patients 
(benefit from use should exceed the risk of adverse side 
effects); economic efficiency – rational use of resources, 
acceptable ratio of costs and results [2]. 
Today, all recommendations for the treatment of 
hypertension are considered to be the main goal of anti-
hypertensive therapy, which is to achieve the target blood 
pressure (BP) level. Another important task is the protec- 
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tion of target organs and the positive impact on the risk 
factors for cardiovascular complications. In this case, 
successful treatment of arterial hypertension remains a 
difficult problem, despite the presence of several classes 
of antihypertensive drugs and efforts to combat the im-
pact of unhealthy lifestyle on blood pressure [3]. 
Considering the socio-economic status of most 
Ukrainian citizens, it is necessary to conduct a permanent 
dynamic pharmaco-economic analysis of minimizing the 
cost of proper medical care and a corresponding revision 
of its standards. 
 
3. Analysis of recent studies and publications in 
which a solution of the problem are described and to 
which the author refers 
The rapid development of the pharmaceutical in-
dustry has led to the emergence of new drugs, which 
must meet modern requirements, namely, the effectiveness 
of exposure should increase with decreasing the cost of the 
drug. Competition among pharmaceutical companies for 
the consumer today has caused a number of clinical prob-
lems. The method of "minimizing costs" makes it possible 
to compare costs with the same therapeutic efficacy, but it 
must be taken into account that the low cost of drugs does 
not always reduce the cost of treatment in general, as it 
leads to complications and reduces the effectiveness of 
medicines [4]. 
World experience of recent decades has shown 
that among the recommended modern antihypertensive 
drugs, angiotensin II receptor blockers (ARB II) occupy 
a deserved place as first-line drugs along with angioten-
sin-converting enzyme inhibitors [3].  
 
4. The field of research considering the general 
problem, which is described in the article 
Patients with hypertension receive courses of 
life-long treatment that require certain economic costs, 
and often the cost of treatment becomes a reason to 
stop taking drugs. Therefore, studies that allow the 
establishment of pharmaco-economic feasibility of the 
use of drugs for the treatment of hypertension are 
relevant. 
 
5. Formulation of goals (tasks) of article 
Therefore, the purpose of our study was to estab-
lish a pharmaco-economic assessment of the use of drugs 
in two groups: candesartan (angiotensin II blockers – 
ARB II) and ramipril (angiotensin converting enzyme 
inhibitors – ACE inhibitors) that are used to treat hyper-
tension based on cost-effectiveness analyzes [5]. 
 
6. Presentation of the main research material 
(methods and objects) with the justification of the 
results 
100 protocols of medical cards of inpatient pa-
tients were investigated. Two groups of patients were 
allocated: the first group for the treatment of hyperten-
sion received angiotensin II blockers (ARB II) (candesar-
tan), and the second group, an angiotensin converting 
enzyme inhibitor, – an ACE inhibitor (ramipril). Atten-
tion was drawn to parameters of the blood pressure level, 
which served as an indicator of the effectiveness of anti-
hypertensive therapy (SAT, DAT). In addition to the 
criteria of effectiveness (achievement of target BP), pos-
sible complications of drug therapy were taken into ac-
count - hypotension, cough, angioneurotic edema. Also, 
the results of biochemical studies (determination of glu-
cose, coagulogram, AST, ALT, creatinine, urea, choles-
terol and beta-lipoproteins) were included in the efficien-
cy criterion. 
To evaluate the cost of treatment against the 
background of the use of ramipril and candesartan, a 
pharmaco-economic cost-effectiveness analysis was 
conducted to determine the optimal, in terms of pharma-
co-economics, an effective drug for the treatment of 
hypertension. 
Research results. Dynamics of indicators of 
blood pressure in patients is presented in the Table. 1. 
 
Table 1 
Dynamics of SAT and DAT levels against the background of treatment with ramipril and candesartan 





 for 1 day of stay of patients in a hospital 
Ramipril 157±11* 98±8** 59±13.67 6.73±2.77 7.03±2.85 
Candesartan 167±24.38* 95±13.78 72±24.09 7.5±2.67 7.5±2.67 
 for 3 day of stay of patients in a hospital 
Ramipril 145±10* 87±9* 56.67±7.3 6.73±2.7 7.03±2.8 
Candesartan 141.66±11.6* 81.66±11.6 58±10.8 7.5±2.6 7.5±2.6 
 for 7 day of stay of patients in a hospital 
Ramipril 131.67±8.3* 77.92±8.9 53.34±10.3 6.73±2.7 7.03±2.8 
Candesartan 131.66±11.6* 77.5±8.8 53.75±13.4 7.5±2.6 7.5±2.6 
 for 10 day of stay of patients in a hospital 
Ramipril 125.84±3.93 73.75±7.1 52.09±10.53 6.73±2.7 7.03±2.8 
Candesartan 130±3.93* 73.83±5.1 53.83±14.67 7.5±2.67 7.5±2.67 
 for 14 day of stay of patients in a hospital 
Ramipril 125±3.93 73.75±7 52±10.53 6.7±2.7 7.0±2.8 
Candesartan 128.84±8.3* 73.8±9.1 53.8±14.6 7.5±2.6 7.5±2.6 
Note: * – p<0.05; ** – p<0.001 
 




Ramipril normalized blood pressure for the first 
day the best (23.8 %) (Table 2), and candesartan did it 
worse (7.4 %). At the 3rd day, the percentage of normali-
zation of blood pressure accounted for 36.9 % and 35.7 
% for ramipril and candesartan respectively. At 10th day 
the leader's position is maintained by ramipril (84.5 %). 
At day 14 ramipril almost in a hundred percent of cases 
stabilized BP (92.8 %). 
The results of the analysis of drug efficacy ex-
pressed in percent demonstrated that ramipril is more 
effective in achieving target blood pressure, but the per-
centage of side effects, including heart failure and cough, 
was significantly higher (Table 3). 
In the 1st group of patients before treatment, glucose 
levels were elevated (6.9±3.27 mmol / l), and after – de-
creased to the normal limits (4.5 mmol / l) (Table 4). 
The level of glucose in the 2nd group before treat-
ment was elevated (6.9±3.27 mmol / l), and after – de-
creased to the limits of the norm (4.7 mmol / l) (Table 4). 
In all groups of patients, the level of plasma re-
calcification time was normal. Hematocrit in the 2nd 
group was normal, and in the 1st – slightly increased. 
The level of the prothrombin index in all groups of 
patients was within the normal range, and the level of 
fibrinogen A (fibrinogen plasma) in all groups was 
elevated (Table 5). 
 
Table 2 
Effectiveness of pharmacotherapy with ramipril and candesartan on the percentage of blood pressure normaliza-
tion 
Drug 1st day, % 3rd day, % 7th day, % 10th  day, % 14th  day, % 
Ramipril 23.8 36.9 73.8 84.5 92.8 
Candesartan 21.1 35.7 54.0 66.7 74.7 
 
Table 3 
Results of the analysis of efficiency 
Drug 
Achievement of the 
target level of BP, % 





Ramipril 85 1.9 9 – 9 
Candesartan 64 3.7 0.4 0.2 0.8 
 
Table 4 
The dynamics of glucose levels in the fasted state and 2 hours after eating 
Drug 
Glucose level in the fasted state, mmol / l Glucose level 2 hours after eating, 
mmol / l before treatment after treatment 
Ramipril 6.9±3.27 4.5±0.06* 7.33±1.79** 
Candesartan 6.9±3.27 4.7±0.06* 7.35±1.79** 
Note: * – p<0.05; ** – p<0.001 
 
Table 5 




Hematocrit, % Prothrombin index, % Fibrinogen А, g/l 
Ramipril 97±13.39* 46.38±6.16 90.83±11.06* 4.05±1.13* 
Candesartan 95±13.57* 43.3±6.95 87.7±8.07* 3.84±1.16* 
Note: * – p<0.05; ** – p<0.001 
 
 
The level of AST and ALT in the 1st and 2nd 
group of patients both before and after treatment was 
within the normal range (Table 5). Creatinine in the 1st 
and 2nd group of patients was normal. The level of urea 
in all groups was within the normal range (Table 6).The 
use of ramipril and candesartan did not affect the level of 
cholesterol, candesartan reduced the level of beta-
lipoproteins in 1.1 times (Table 7). 
 
Table 6 
Dynamics of levels of AST and ALT, urea and creatinine 
Drug 
AST, mmol / h l ALT, mmol / h l 
Creatinine, 
μmol / l 








Ramipril 0.39±0.15 0.35±0.21 0.55±0.28 0.55±0.21 88.78±22.46* 6.41±1.16* 
Candesartan 0.44±0.21 0.3±0.14* 0.53±0.12 0.5±0.2 93.15±13.17* 6.79±1.77* 









Dynamics of cholesterol and beta-lipoprotein levels 
Drug 
cholesterol, mmol / l Beta-lipoprotein, units 
before treatment after treatment before treatment after treatment 
Ramipril 5.04±1.46 5.08±1.32 47.96±13.54 49.8±10.02* 
Candesartan 5.52±1.71 5±1.69 55.12±17.09 50±14.14** 
 
Using the “cost-effectiveness method”, an ACE 
inhibitor (ramipril) and ARB inhibitor (candesartan) 
were analyzed. 
Data on the cost (minimum, average and maxi-
mum) of ACE inhibitor (in UAH) were taken at the end 
of the study (April-May 2017) from the network of 
pharmacies in Chernivtsi – “Vako”, “Harmony”, and 
“Econom-pharmacy” and “Olmamed”. 
Calculation of the cost of the ACE inhibitor and 
ARB inhibitor was carried out in stages: 
– values of "cost" of normalization of blood pres-
sure: the value of the daily dose is multiplied at the bot-
tom of the normalization of blood pressure; 
– "cost" of the course dose: the value of the daily 
dose is multiplied by the number of bed days. The mini-
mum, average and maximum values of ACE inhibitor 
and ARB inhibitor were taken into account. 
The indicator of the effectiveness of treatment 
was calculated as the ratio of the number of persons with 
the target level of blood pressure to the number of per-
sons in whom the blood pressure did not reach the target 
level. 
Thus, the efficiency indicator was for: 1st group – 
22/25=0.88; 2nd group – 13.18=0.72. 
Calculated expense – intermediate-effect (reflects 
the cost of normalization of blood pressure) and cost-
efficiency indicator. 
Regarding the analysis of the range of prices for 
the drug "Ramipril," we found the following: the drug at 
a dose of 5 mg (tab. 30) was the cheapest for the patient 
at the pharmacy "Econom-pharmacy" (129.50 UAH.). 
This dosage at the time of the study was absent in 
the pharmacy "Harmony" and "Olmamed"; for the drug 
at a dose of 10 mg (tab. 30) the lowest price was – at the 
pharmacy "Econom-pharmacy" (250.50 UAH.), and the 
highest one – in the pharmacy "Olmamed" and "Vako" 
(265.00 UAH, respectively the same).  
For "Candesartan" – 16 mg (tab. 28) the lowest 
price was – in the pharmacy "Economy-pharmacy" 
(378.50 UAH.), and the highest one – in the pharmacy 
"Olmamed" and "Vako" (431.00 UAH, respectively, the 
same). 
At the time of research, ramipril was on average in 
pharmacies in the city of Chernivtsi with the price within 
the limits of 158.50 UAH for 5 mg of dosage form N 30 
(Table 8). Candesartan –16 mg (tab. 28) – 431.00 UAH.  
Taking into account the above, we calculated the 
minimum, average and maximum values of one-time, 
daily and course dose. Also calculated the cost of nor-
malization of blood pressure. The data is presented in the 
Table. 9. 
Comparison of the values of single-dose for rami-
pril dose is up to 10.50 UAH, and the lowest single dose 
price for candesartan is 15.39 UAH. 
 
Table 8 
Averaged prices of ramipril and candesartan of ramipril group per 1 pack. 
Drug 
Average packing cost, UAH 
Minimal Average Maximal 
Ramipril mg № 30 127.00 158.50 190.00 
Candesartan 4 mg № 28 (Actavis (Slovakia) 16 mg № 28) 378.00 431.00 469.00 
 
Table 9 
Indicator of the averaged cost of single doses of ramipril and candesartan 
Drug 
Cost of single doses, UAH 
Single dose 
Minimal Average Maximal 
Ramipril 8.40 10.50 12.60 
Candesartan 13.50 15.39 16.75 
Drug 
Cost of course (14 days) dose, UAH 
Minimal Average Maximal 
Ramipril 118.46 147.86 176.40 
Candesartan 189.00 215.44 234.50 
Drug 
Cost of course dose, UAH, 1 month 
Minimal Average Maximal 
Ramipril 236.92 294.00 352.00 
Candesartan 333.00 430.88 469.00 
Drug 
Cost of course dose (3 months), UAH 
Minimal Average Maximal 
Ramipril 710.10 882.00 1056.00 
Candesartan 999.00 1292.64 1407.00 
  




Analysis of patients' expenditure to achieve the 
target blood pressure level when compared to 5 mg rami-
pril and 8 mg of candesartan showed that they would 
have the least amount of money in the use of ramipril 
than candesartan. 
The data we receive show that ramipril is more ef-
fective as a hypotensive agent and because of the key 
importance of the renin-angiotensin system in the patho-
genesis of AH, the use of ARB is pathogenetically 
grounded, an alternative ACE inhibitor.  
For medications from the ARB group, there is 
still no advantage over ACE inhibitors over the 
course of AH and survival prediction. At the same 
time, the feasibility of their clinical application can 
be determined by the safety and better portability of 
ARBs [6, 7]. 
In CHARM-Alternative studies, 2028 patients 
were included in which ACE inhibitors could not be 
administered in view of side effects, the use of candesar-
tan allowed to reduce the probability of a primary end-
point by 23 %. Thus, ARBs should be the means of 
choice in patients with hypertension that do not tolerate 
ACE inhibitors [8–10]. 
A double-blind study comparing the efficacy of 
ARB valsartan, ACE inhibitor captopril found that 
valsartan did not yield captopril for its effectiveness in 
hypertension. In monotherapy, hypotension and renal 
failure were more common in the valsartan group, and 
cough, rash and taste disturbance - when taking capto-
pril [11–13]. 
Researchers have found that both effective and in-
effective therapy with ACE inhibitors during the month 
of changes in aggregation capacity of blood is not ob-
served, but treatment within six months can give positive 
results on the parameters of the biochemical analysis of 
blood and also cause lower cholesterol, triglycerides and 
low density lipoprotein [14, 15].  
 
7. Conclusions from the conducted research 
and prospects for further development of this field 
The obtained data indicate the high therapeutic ef-
fectiveness of candesartan and ramipril, which makes it 
possible to make the following conclusions: 
1. The most effective target for BP was ramipril 
compared with candesartan, although the effects of drugs 
on lipid spectrum, coagulogram, glucose, and ALT and 
AST levels were practically the same. 
2. An analysis of the efficacy of medicinal prod-
ucts found that ramipril has side effects and causes cough 
and heart failure, and candesartan can cause angioedema 
and hypotension. 
3. During the analysis of direct costs for treatment 
of hypertension, based on the existing standards for the 
provision of medical care to patients with hypertension, it 
was found that treatment with ramipril is the least costly. 
4. The "cost-effectiveness" analysis showed that 
the largest pharmaco-economic advantage in pharma-
cotherapy AH is ramipril, because this therapy requires 
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INFLUENCE OF EXTRACT OF PEACH ORDINARY (PERSICA VULGARIS) LEAVES ON 
THE STATE OF THYMIC-LYMPHATIC ELEMENT OF THE IMMUNE SYSTEM OF RATS 
IN CONDITIONS OF CHRONIC IMMOBILIZATION STRESS 
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Мета – вивчення впливу густого екстракту з листя персика звичайного (ГЕЛП) на стан органів тиміко-
лімфатичної ланки імунної системи щурів за умов хронічного іммобілізаційного стресу.  
Матеріали та методи. Модель хронічного іммобілізаційного стресу (ХІС) відтворювали протягом 18 
діб шляхом щоденної чотирьохгодинної іммобілізації щурів у тісних пеналах. Досліджуваний ГЕЛП, що 
був отриманий на кафедрі хімії природних сполук НФаУ, з листя персика сорту «Сальве», заготовленого 
в Таджикистані, вводили внутрішньошлунково в умовноефективній дозі 100 мг/кг. Як препарат порів-
няння використовували сироп «Імуно-Тон» у дозі 3 мл/кг внутрішньошлунково. Стан тиміко-
лімфатичної ланки імунної системи в умовах ХІС визначали після проведення евтаназії тварин під лег-
ким інгаляційним наркозом за результатами дослідження коефіцієнтів маси тимуса і селезінки, а та-
кож гістологічного дослідження їх структури на мікропрепаратах, що були приготовлені за загальноп-
рийнятою методикою. Для оцінки характеру впливу ГЕЛП на стан органів тиміко-лімфатичної систе-
ми щурів в умовах ХІС проводили порівняння з інтактним контролем та контрольною патологією. 
Результати дослідження. Встановлено протективний вплив ГЕЛП на стан тиміко-лімфатичної ланки 
імунної системи в умовах ХІС. У селезінці відмічали збільшення ширини маргінальної зони лімфоїдних 
фолікулів і муфт та кількості периваскулярних лімфатичних муфт у 1,2 разу (р<0,05) порівняно з конт-
рольною патологією, зниження ознак стресогенної гіпоксії – кількості структур білої пульпи зі спазмом 
центральних артерій. У тимусі встановлено зниження ступеня змін з третьої-четвертої до першої фа-
зи акцидентальної трансформації, що підтверджується підвищенням коефіцієнту маси тимуса на 2,7 
% порівняно з контрольною патологією. 
Висновки. Доведена здатність ГЕЛП відновлювати порушену в умовах стресу активність органів ти-
міко-лімфатичної ланки імунної системи. Ймовірно стверджувати, що поліфенольні сполуки ГЕЛП ви-
являють антиоксидантні властивості, посилюючи активність антиоксидантної системи, а полісаха-
риди  імуностимулювальні, результатом виявлення яких є стреспротекторна дія. За ефективністю 
ГЕЛП не поступався препарату порівняння «Імуно-Тон» 
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Stress is a universal physiological response to ra-
ther strong effects, which is aimed at mobilizing com-
pensatory mechanisms that can be manifested by the 
transition from activation of the physiological apparatus 
to exhaustion as a result of overstrain of the reserve ca-
pacity of the organism. Stress can cause factors such as 
injury, loss of blood, surgical intervention, high and low 
